MGI, a subsidiary of Shenzhen-based BGI and Complete Genomics, had settled litigation in the U.S. over DNA-sequencing technology with their rival Illumina Inc., MGI said in a release Friday.
Illumina has agreed to pay US$325 million to end the U.S. litigation, following recent jury verdicts in patent cases in California and Delaware. The settlement also resolved a pending antitrust lawsuit by MGI against Illumina in California.
Complete Genomics, a U.S. subsidiary of MGI, and San Diego-based Illumina are both major providers of genome-analysis technology used to detect genetic diseases. A Delaware jury awarded Complete Genomics US$333 million in May after finding Illumina’s “two-channel” sequencing systems and kits to prepare DNA fragments for sequencing violated its patent rights. Illumina earlier won US$8 million and a temporary ban on U.S. sales of some BGI Group sequencers based on its own patent claims in a San Francisco federal court.